These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 33448873)

  • 1. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CAR-T cells in lymphomas: Current and evolving role].
    Messéant O; Houot R
    Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
    Jacobson CA; Farooq U; Ghobadi A
    Oncologist; 2020 Jan; 25(1):e138-e146. PubMed ID: 31585984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
    Locke FL; Go WY; Neelapu SS
    JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
    Deshpande A; Wang Y; Munoz J; Jain P
    Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
    Othman T; Baird JH; Pak S; Mei M; Herrera AF; Mansour J; Shouse G; Sahebi F; Spielberger R; Cai JL; Farol L; Godfrey J; Kallam A; Phillips T; Popplewell L; Siddiqi T; Forman S; Budde LE
    Br J Haematol; 2024 Jul; 205(1):368-372. PubMed ID: 38797530
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in chimeric antigen receptor T cells.
    Beyar-Katz O; Gill S
    Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
    Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
    Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
    Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
    Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
    Dholaria B; Mehraban N; Baer B; Long N; Jayani RV; Byrne MT; Kassim AA; Engelhardt BG; Savani BN; Oluwole OO
    Br J Haematol; 2022 Sep; 198(6):1073-1075. PubMed ID: 35765247
    [No Abstract]   [Full Text] [Related]  

  • 18. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
    Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
    Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
    Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
    Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
    J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.